Register Login

Ultragenyx Pharmaceutical Inc (RARE)

  • Event
  • July 18, 2022, 20:12 UTC

(10% Negative) Ultragenyx Pharmaceutical Inc. (RARE) Announces Delay in improvement Trials for multiple domains U Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 3:29 p.m.

    📋 Ultragenyx Pharmaceutical Inc. (RARE) - Clinical Trial Update

    Filing Date: 2022-07-18

    Accepted: 2022-07-18 16:12:15

    Event Type: Clinical Trial Update

    Event Details:

    Ultragenyx Pharmaceutical Inc (RARE) Announces Clinical Trial Update Ultragenyx Pharmaceutical Inc (RARE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: improvement, patient
    • Diseases/Conditions: multiple domains U
    • Clinical Stage: Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: for Angelman Syndrome Inc
      • planned for 5 p.m. Eastern Time NOVATO, Calif. — July 18, 2022

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ultragenyx Pharmaceutical Inc
    • CIK: 0001515673
    • Ticker Symbol: RARE
    • Period End Date: 2022-07-15
    • Document Type: 8-K

Search

News categories